Aradigms initial U.

Aradigm’s initial U.S .S. Of SUMAVEL* DosePro* needle-free of charge delivery system. The ongoing company will receive quarterly royalty payments on all SUMAVEL DosePro sales. In 2006, the business sold all assets linked to the Intraject* needle-free injector technology to Zogenix in trade for milestone and royalty payments.S. Meals and Medication Administration approved SUMAVEL DosePro for the acute treatment of migraine, with or without aura, and the acute treatment of cluster head aches. SUMAVEL DosePro delivers subcutaneous sumatriptan, a treatment that provides migraine comfort, in a first-of-its-kind needle-free delivery system.

precio Kamagra 100mg barcelona

ArQule reports net lack of $7,141,000 in first quarter 2014 ArQule, Inc. today announced its economic results for the 1st quarter of 2014.11 per talk about, compared to a net loss of $5,775,000, or $0.09 per share, for the first quarter of 2013. At March 31, 2014, the Company had a total of $85,758,000 in cash, equivalents and marketable securities. Operational Revise Enrollment is usually proceeding in the Stage 3 METIV-HCC trial of tivantinib in hepatocellular carcinoma conducted by ArQule and its partner, Daiichi Sankyo Co., in the U.S. And Europe; Kyowa Hakko Kirin, the Business's partner in Asian territories, in February initiated the Phase 3 JET-HCC trial of tivantinib in HCC in Japan, 2014; Patient enrollment is normally continuing in several NIH-sponsored trials with tivantinib, including Phase 2 randomized trials in prostate cancer, neck and head cancer, and kidney cancer; The dosage escalation portions of Phase 1 trials with the Firm's proprietary compounds, ARQ 092 and ARQ 087, are nearing completion.

Other entries from category "psychoanalysis":

Tag Cloud